Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
- 16 June 2009
- journal article
- editorial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (24) , 9546-9547
- https://doi.org/10.1073/pnas.0904560106
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences, 2009
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptorBiochemical Journal, 2009
- PCSK9: a convertase that coordinates LDL catabolismJournal of Lipid Research, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptideBiochemical and Biophysical Research Communications, 2008
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotypeProceedings of the National Academy of Sciences, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986